News

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.

This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.

Teva presents 2 findings at the 2024 psychiatry conference: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

MASEF score seemed to be sensitive and effective in detecting at-risk MASH in 2 abstracts presented at the ACG 2024 Meeting.

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

Direct-acting antiviral agents have enabled more availability for organ transplant.

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

Alcohol relapses were detected more frequently after the introduction of phosphatidylethanol in orthotopic liver transplant recipients.

Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.

Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.

The oral therapy may address limitations including difficulty in application and adverse events with topical therapies.

According to Phase 3 LIBERTY-CUPID trial results, dupilumab significantly reduces itch and hive activity from baseline in chronic spontaneous urticaria.

In this Month in Review summary, some of the most notable advancements and developments in the field of dermatology were highlighted.

Clinical images help pathologists improve diagnostic confidence and agreement, leading to more accurate diagnoses of melanocytic skin lesions.

Risankizumab achieves significantly higher rates of skin clearance and improved quality of life versus deucravacitinib in matching-adjusted indirect comparison analysis.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

The approval by the FDA of minocycline hydrochloride modified release capsules, also known as DFD-29, will allow for treatment of inflammatory lesions and erythema among adults.

In this analysis, investigators identified several markers such as monocyte-high-density lipoprotein cholesterol ratio and C-reactive protein values.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

Neither clinician peer comparison nor patient informational mail reduced benzodiazepine use among older adults in anesthesia care, a new study finds.